What is PanCareSurFup

 

Five-year survival after cancer during childhood or adolescence is now almost 80% in most developed countries. The growing numbers of survivors brings increasing concern about the long-term consequences of treatment to growing organs and tissues. As part of a pan-European network of professionals and survivors and their families, PanCareSurFup, a new FP7-funded project, will carry out a series of epidemiologic studies of the most serious complications of long-term survival. Sixteen European networks and institutions will follow about 80,000 survivors of childhood and adolescent cancer, making PanCareSurFup the largest study of its kind to date.

• Cohort-based risk assessments of all second malignancies, cardiac disease and late mortality, that is, deaths after 5 year from diagnosis

• Nested case-control-based risk assessments for cardiac disease, subsequent primary sarcomas and subsequent primary carcinomas

Over five years (2011 – 2016), PanCareSurFup will develop risk estimates for cardiac disease, second cancers and late mortality. A key component will be establishing the doses of radiotherapy to each organ, enabling tighter estimates of risk. These data, with results from other studies, will be the basis for establishing guidelines for follow-up in Europe, including suggestions for clinical networks to enable care to continue seamlessly from paediatric to adult settings. Finally, dissemination of the results will be achieved through conferences, workshops, newsletters and blogs, and partnerships with survivors and parents. PanCareSurFup’s studies are intended to lead to increased cooperation between treatment and advocacy groups, reduce disparities in survival and improve outcomes for children and adolescents diagnosed with cancer in Europe.